Taiwan · Delayed Price · Currency is TWD Oneness Biotech Company Description
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan.
It offers Fespixon cream for diabetic foot ulcers. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials.
It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase II clinical trials; and SNS851 for weight loss and metabolism diseases.
In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products.
Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Shuling Cheng |
Contact Details
Address: No. 66, Zhonzheng W. Rd. Taipei, 100 Taiwan | |
| Phone | 886 2 2703 1098 |
| Website | onenessbio.com |
Stock Details
| Ticker Symbol | 4743 |
| Exchange | Taipei Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0004743000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nien-Yi Chen | Deputy General Manager of Antibody New Drug Division; |
| Dr. Shuling Cheng Ph.D. | President |
| Ting-Fang Chen | Financial Officer and Acting Spokesperson |
| Ai-Chia Yu | Accounting Officer |
| Dr. Jui-Ching Chen Ph.D. | Director of New Drug Development Department |
| Kung-Ming Lu | Director of Operation Center |
| Tzu-Chun Yang | Associate General Manager of Information Technology Department |